Literature DB >> 17618113

Novel inhibitor for fibroblast growth factor receptor tyrosine kinase.

Naparat Kammasud1, Chantana Boonyarat, Satoshi Tsunoda, Hiroaki Sakurai, Ikuo Saiki, David S Grierson, Opa Vajragupta.   

Abstract

NP603, the 6-dimethoxy phenyl indolin-2-one, was designed as FGF receptor 1 inhibitor by computational study. NP603 was synthesized and found to be more active against endothelial proliferation of HUVEC after the rhFGF-2 stimulation than SU6668 with minimum effective dose of 0.4 microM but with similar potency as SU16g. NP603 inhibited the tyrosine phosphorylation in FGF receptor and the activation of extracellular signal-regulated kinase and c-Jun-N-terminal-kinase after the rhFGF-2 stimulation. The increase in activity of NP603 supports the role of Lys514 movement in ligand-receptor binding in modeling study as the movement accommodates the hydrophobic interaction at the receptor pocket leading to the enhancement of binding capacity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17618113     DOI: 10.1016/j.bmcl.2007.06.058

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  7 in total

1.  A structure-guided approach to creating covalent FGFR inhibitors.

Authors:  Wenjun Zhou; Wooyoung Hur; Ultan McDermott; Amit Dutt; Wa Xian; Scott B Ficarro; Jianming Zhang; Sreenath V Sharma; Joan Brugge; Matthew Meyerson; Jeffrey Settleman; Nathanael S Gray
Journal:  Chem Biol       Date:  2010-03-26

2.  Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.

Authors:  Li Tan; Jun Wang; Junko Tanizaki; Zhifeng Huang; Amir R Aref; Maria Rusan; Su-Jie Zhu; Yiyun Zhang; Dalia Ercan; Rachel G Liao; Marzia Capelletti; Wenjun Zhou; Wooyoung Hur; NamDoo Kim; Taebo Sim; Suzanne Gaudet; David A Barbie; Jing-Ruey Joanna Yeh; Cai-Hong Yun; Peter S Hammerman; Moosa Mohammadi; Pasi A Jänne; Nathanael S Gray
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-27       Impact factor: 11.205

3.  Wnt9b-dependent FGF signaling is crucial for outgrowth of the nasal and maxillary processes during upper jaw and lip development.

Authors:  Yong-Ri Jin; Xiang Hua Han; Makoto M Taketo; Jeong Kyo Yoon
Journal:  Development       Date:  2012-03-29       Impact factor: 6.868

4.  HTRF: A technology tailored for drug discovery - a review of theoretical aspects and recent applications.

Authors:  François Degorce; Amy Card; Sharon Soh; Eric Trinquet; Glenn P Knapik; Bing Xie
Journal:  Curr Chem Genomics       Date:  2009-05-28

5.  Dual inhibitors of hepatitis C virus and hepatocellular carcinoma: design, synthesis and docking studies.

Authors:  Mostafa Mm El-Miligy; Samia M Rida; Fawzia A Ashour; Mona H Badr; Ehab M El-Bassiony; Maha A El-Demellawy; Ashraf M Omar
Journal:  Future Sci OA       Date:  2017-10-25

6.  Identification and validation of an inflammation-related lncRNAs signature for improving outcomes of patients in colorectal cancer.

Authors:  Mengjia Huang; Yuqing Ye; Yi Chen; Junkai Zhu; Li Xu; Wenxuan Cheng; Xiaofan Lu; Fangrong Yan
Journal:  Front Genet       Date:  2022-09-30       Impact factor: 4.772

7.  Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells.

Authors:  Pol Gimenez-Xavier; Eva Pros; Ana Aza; Sebastian Moran; Raul Tonda; Anna Esteve-Codina; Marc Dabad; Montse Sanchez-Cespedes
Journal:  Oncotarget       Date:  2018-07-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.